Baghalipour Nasimeh, Moztarzadeh Omid, Micopulos Christos, Samara Walla, Hauer Lukas
Department of Stomatology, Faculty of Medicine in Pilsen, Charles University, University Hospital Pilsen, Pilsen, CZE.
Department of Anatomy, Faculty of Medicine in Pilsen, Charles University, University Hospital Pilsen, Pilsen, CZE.
Cureus. 2025 Jun 24;17(6):e86645. doi: 10.7759/cureus.86645. eCollection 2025 Jun.
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse event that occurs in patients treated with certain medications, leading to a major side effect that can result in substantial morbidity. MRONJ is known to be associated with antiresorptive (AR) and antiangiogenic (AA) medicines, but recent evidence suggests that other medications may also be involved. Recognizing a broad range of drug-induced risk factors is important, notably in light of the increasing number of drugs associated with MRONJ. The primary objective of this review is to update and synthesize findings from the past 22 years (2003 to April 2025) regarding medications associated with MRONJ, expanding beyond the traditional AR and AA drugs to include more recent and developing therapeutic classes. This review combines findings from recent literature, including studies on AR and AA medications, as well as other drug classes, such as targeted cancer therapies and immunomodulatory agents. This review provides updated insights into MRONJ for healthcare practitioners and dentists, emphasizing the significance of risk assessment, early recognition, and multidisciplinary management to improve patient care and outcomes. Given its potential to cause significant morbidity and complicate dental and medical treatments, MRONJ presents a critical concern in clinical practice, underscoring the need for heightened awareness among healthcare professionals.
药物相关性颌骨坏死（MRONJ）是一种发生在接受某些药物治疗患者身上的严重不良事件，会导致一种可能引发严重发病情况的主要副作用。已知MRONJ与抗吸收（AR）和抗血管生成（AA）药物有关，但最近的证据表明其他药物可能也与之相关。认识到广泛的药物诱导风险因素很重要，特别是鉴于与MRONJ相关的药物数量不断增加。本综述的主要目的是更新和综合过去22年（2003年至2025年4月）关于与MRONJ相关药物的研究结果，将范围从传统的AR和AA药物扩展到包括更新的和正在发展的治疗类别。本综述结合了近期文献的研究结果，包括关于AR和AA药物以及其他药物类别（如靶向癌症治疗药物和免疫调节剂）的研究。本综述为医疗从业者和牙医提供了关于MRONJ的最新见解，强调了风险评估、早期识别和多学科管理对改善患者护理和治疗结果的重要性。鉴于其可能导致严重发病并使牙科和医疗治疗复杂化，MRONJ在临床实践中是一个关键问题，凸显了医疗专业人员提高认识的必要性。
